Primary malignant mesothelioma (MPM) is a rare malignancy that arises from the epithelial cells that line visceral cavities. The primary pleural presentation is known as the most commonly seen presentation and is best recognized clinically. Less commonly, mesothelioma can arise from epithelial cells lining other visceral cavities, including the … [Read more...]
GLP-1 RA Drug NAION Cases: Medical and Legal Updates October 2025
GLP-1 RA Drug NAION Cases: Possible Drug Injury Lawsuits We are investigating possible drug injury lawsuits where people using glucagon-like peptide-I receptor agonist (GLP-1 RA) drugs were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), resulting in vision loss or blindness. Those GLP-1 RA drug NAION cases involve these … [Read more...]
Dupixent Legal and Medical Information About T-cell Lymphoma
In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect. We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, based on … [Read more...]
Chrysotile asbestos—the deadly consequences of a retreat from national bans
Many in the global clinical and research community reacted with horror to the June 18, 2025, news that the Trump administration was requesting that the US Environmental Protection Agency (US EPA) should “reconsider” the country’s ban on chrysotile asbestos. This ban had been previously enacted under the Biden presidency in 2024. Arguing that the … [Read more...]
Dupixent Cancer Lawsuits: Legal and Medical Update
We are currently investigating possible Dupixent cancer lawsuits for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent. The Dupixent cancer lawsuits would be filed against the manufacturers of Dupixent, Sanofi and Regeneron, based on … [Read more...]
Increased Risk of NAION Associated With Ozempic and Mounjaro
A 2025 medical study concluded that there is an increased risk of NAION associated with Ozempic and Mounjaro. In more detail, the researchers considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to … [Read more...]
Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for selected patients. The purpose of this study was to thoroughly examine the impact of the combined treatment and the prognostic variables, particularly the … [Read more...]
Long Road to Identifying Peritoneal Mesothelioma: An Elusive Diagnosis
Peritoneal mesothelioma is a rare and aggressive malignancy [ of the peritoneum ] that often presents with non-specific abdominal symptoms such as ascites, leading to delayed diagnosis and treatment. It poses significant diagnostic challenges, especially in the absence of classical risk factors like asbestos exposure. We report the case of a … [Read more...]
NAION With Mounjaro and Zepbound Being Investigated
The FDA is investigating the possible connection of NAION with Mounjaro and Zepbound, according to “October – December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)”. During the past year, we have written about the vision loss side effect NAION (non-arteritic … [Read more...]
Semaglutide NAION Side Effect Can Be Part of a Vision Loss AION Diagnosis
The European Medicines Agency (EMA) confirmed the link between the active ingredient in Ozempic, semaglutide, and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator said further that a semaglutide NAION side effect warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, … [Read more...]
- 1
- 2
- 3
- …
- 23
- Next Page »